Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): A systematic literature review of randomized controlled trials

Rheumatology International

Volumn 33, Issue 5, 2013, Pages 1105-1120

  Steiman, Amanda J ^a   Pope, Janet E ^b   Thiessen Philbrook, Heather ^b   Li, Lihua ^b   Barnabe, Cheryl ^c   Kalache, Fares ^d   Kung, Tabitha ^a   Bessette, Louis ^e   Flanagan, Cathy ^f   Haraoui, Boulos ^g   Hochman, Jacqueline ^a   Leclercq, Sharon ^c   Mosher, Dianne ^h   Thorne, Carter ^a   Bykerk, Vivian ^a,i  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g NOTRE DAME HOSPITAL   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Ankylosing; Antirheumatic agents; Arthritis; Pain; Pain measurement; Psoriatic; Rheumatoid; Spondylitis

Indexed keywords

AURANOFIN; CHLOROQUINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE;

ANALGESIA; ANKYLOSING SPONDYLITIS; ARTHRALGIA; DISEASE DURATION; DRUG EFFECT; DRUG RESPONSE; HUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRALGIA; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; EVIDENCE-BASED MEDICINE; HUMANS; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878016595     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2619-6     Document Type: Review

References (56)

1. Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthr Rheum 43:22-29
2. Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS (2004) Benefit of very early referral and very early therapy with disease-modifying anti- rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43:906-914
3. Bukhari MAS, Wiles NJ, Lunt BJ, Scott DGI, Symmons DPM, Silman AJ (2003) Influence of disease modifying therapy on radiographic progression in inflammatory polyarthritis at five years. Arthr Rheum 48:46-53
4. Wiles NJ, Lunt M, Barrett EM, Bukhari M, Silman AJ, Symmons DP et al (2001) Reduced disability at 5 years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthr Rheum 44:1033-1042
5. The diagnosis and treatment of early psoriatic arthritisAnandarajah (2009) Allen P and Ritchlin, Christopher T. Nature reviews. Rheumatology 5(11):634-641
6. Olivieri I, D'Angleo S, Palazzi C, Padula A (2010) Advantages in early recognition and treatment of psoriatic arthritis Int. J Clin Rheumatol 5(4):461-473
7. Salvarani C, Cantini F, Olivieri I (2002) Disease-modifyingantirheumatic drug therapy for psoriatic arthritis. Clin Exp Rheumatol 20(6):S71-S75
8. Whittle SL, Colebatch AN, Buchbinder R, Edwards CJ, Adams K, Englbrecht M, Hazlewood G, Marks JL, Radner H, Ramiro S, Richards BL, Tarner IH, Aletaha D, Bombardier C, Landewe RB, MuÂ̈ller-Ladner U, Bijlsma JWJ, Branco JC, Bykerk VP, da Rocha G, Pinheiro C, Catrina AI, Hannonen P, Kiely P, Leeb B, Lie E, Martinez-Osuna P, Montecucco C, Østergaard M, Westhovens R, Zochling J and van der Heijde D (2012) Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology. doi: 10.1093/rheumatology/ kes032
9. Higgins JPT, Altman DG (eds) (2008) Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. Version 5.0.1 [updated September 2008]. Cochrane Collab. Available from www.cochrane-handbook.org
10. Thiessen Philbrook H, Barrowman N, Garg AX (2007) Imputing variance estimates do not alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal function after living kidney donation. J Clin Epi 60:228-240
11. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
12. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
13. Fink A, Kosecoff J, Chassin M, Brook RH (1984) Consensus methods: characteristics and guidelines for use. Am J Public Health 74:979-983
14. Altan L, Bingöl Ü, Karakoç Y et al (2001) Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 30:255-259
15. Clegg DO, Reda DJ, Weisman MH et al (1996) Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthr Rheum 39:2004-2012
16. Corkill MM, Jobanputra P, Gibson T, Macfarlane DG (1990) A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Br J Rheumatol 29:41-45
17. Dougados M, Boumier P, Amor B (1986) Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J 293:911-914
18. Dougados M, van der Linden S, Leirisalo-Repo M et al (1995) Sulfasalazine in the treatment of spondylarthropathy. Arthr Rheum 38:618-627
19. Marzo-Ortega H, McGonangle D, Jarrett S et al (2005) Infliximab in combination with methorexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568-1575
20. Nissilä M, Lehtinen K, Leirisalo-Repo M et al (1988) Sulfasalazine in the treatment of ankylosing spondylitis. Arthr Rheum 31:1111-1116
21. Taylor HG, Beswick EJ, Dawes PT (1991) Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 10:43-48
22. van Denderen JC, van der Paardt M, Nurmohamed MT et al (2005) Double blind, randomized, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 64:1761-1764
23. Carette S, Calin A, McCafferty JP, Wallin B (1989) A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthr Rheum 32:158-165
24. Combe B, Goupille P, Kuntz JL et al (1996) Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 35:664-668
25. Farr M, Kitas GD, Waterhouse L et al (1990) Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 29:46-49
26. Fraser AD, van Kuijk WR, Westhovens R et al (2005) A randomized, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64:859-864
27. Fraser SM, Hopkins R, Hunter JA et al (1993) Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 32:923-925
28. Palit J, Hill J, Capell HA et al (1990) A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 29:280-283
29. Borg G, Allander E, Lund B et al (1988) Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind, placebo controlled study. J Rheumatol 15:1747-1754
30. Clark P, Casas E, Tugwell P et al (1993) Hydroxychloroquine compared to placebo in rheumatoid arthritis. Ann Intern Med 119:1067-1071
31. Esdaile JM, Suissa S, Shiroky JB et al (1995) A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am J Med 98:156-168
32. Gerards AH, Landewé RBM, Prins APA et al (2003) Cyclosporin A monotherapy versus cyclosporine A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomized placebo controlled trial. Ann Rheum Dis 62:291-296
33. Haagsma CJ, van Riel PICM, De Jong AJL, Van de Putte LBA (1997) Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized controlled, double-blind, 52 week clinical trial. Br J Rheumatol 36:1082-1088
34. Hannonen P, Möttönen T, Hakola M, Oka M (1993) Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthr Rheum 36(11):1501-1509
35. Kekow J, Moots RJ, Emery P et al (2010) Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 69:222-225
36. Lerndal T, Svensson B (2000) A clinical study of SPH 82 vs methotrexate in early rheumatoid arthritis. Rheumatology 39:316-320
37. Miranda JM, Alvarez-Nemegyei J, Saaverdra MA et al (2004) A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis. Arch Med Res 35:36-42
38. Bombardier C, Ware J, Russell IJ et al (1986) Auranofin therapy and quality of life in patients with rheumatoid arthritis. Am J Med 81:565-578
39. Dougados M, Awada H, Amor B (1988) Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 47:127-133
40. Førre Ø et al (1994) Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Arthr Rheum 37:1506-1512
41. Glennas A, Kvien TK, Andrup O et al (1997) Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Br J Rheumatol 36:870-877
42. Pullar T, Hunter JA, Capell HA (1983) Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J 287:1102-1104
43. Smolen JS, Kalden JR, Scott DL et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. Lancet 353:259-266
44. Strand V, Cohen S, Schiff M et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 159:2542-2550
45. Tugwell P, Bombardier C, Gent M et al (1990) Low-dose cyclosporine versus placebo in patients with rheumatoid arthritis. Lancet 335:1051-1055
46. Ward JR, Williams HJ, Egger MJ et al (1983) Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis. Arthr Rheum 26:1303-1313
47. Williams HJ, Willkens RF, Samuelson CO Jr et al (1985) Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthr Rheum 28:721-730
48. Williams HJ, Ward JR, Dahl SL et al (1988) A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthr Rheum 31:702-713
49. Salaffi F, Stancati A, Silvestri CA et al (2004) Minimal clinically important changes in chronic musculoskeletal pain intensity measure on a numerical pain rating scale. Eur J Pain 8:283-291
50. Pope JE, Khanna D, Norrie D, Ouimet JM (2009) The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinically practice is smaller than in randomized controlled trials. J Rheumatol 36:254-259
51. Kwok T, Pope JE (2010) Minimally important difference for patient-reported outcomes in psoriatic arthritis: health assessment questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol 37:1024-1028
52. Wheaton L, Pope J (2009) The minimally important difference (MID) for patient centred outcomes in ankylosing spondylitis (AS) including pain, fatigue, sleep and health assessment questionnaire (HAQ). J Rheumatol 36:2579
53. Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthr Rheum 33:1449-1461
54. Anderson JJ, Baron G, van der Heijde D et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthr Rheum 44(8):1876-1886
55. Cunha-Miranda L, Costa L, Ribeiro JS (2010) NEAR study: needs and expectations in rheumatoid arthritis - do we know our patients' needs? Acta Reumatologica Portuguesa 35:314-323
56. Kvamme MK, Kristiansen IS, Lie E, Kvien TK (2010) Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 37:26-31